- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03655431
Home Exercise Telerehabiliation for MS
April 5, 2021 updated by: Shane.Chanpimol
Telerehabilitation Using Kinect-based VR to Improve Mobility and Fatigue in Veterans With MS
The primary purpose of this study is to evaluate the effects of an individualized telerehabilitation program on mobility, fatigue, and quality of life for Veterans with MS.
The secondary purpose was to assess adherence to exercise recommendations and overall satisfaction with the intervention.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20422
- Washington DC VAMC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Clinical diagnosis of MS based on the McDonald criteria
- Expanded Disability Status Scale (EDSS) of 3.0 - 6.5
- Cognitive ability (Montreal Cognitive Assessment score >23/30)
- Physician clearance for exercise participation
- Physical therapy referral
Exclusion Criteria:
- MS-related exacerbation within last 3 months
- Unstable cardiac or pulmonary disease
- Active substance abuse
- Uncontrolled seizures
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Telerehabilitation
Physical therapists will develop an individualized program lasting 12 weeks depending on the needs of a given patient.
Veterans will be seen 1 day/week via clinical video teleconferencing (CVT) for treatment.
The rehabilitation protocol will last approximately 30 minutes with activities that are individualized to meet the participant's needs (range of motion, balance, strengthening, endurance, and functional activities).
Patients assigned to telerehabilitation will utilize the VITAL rehab unit with Jintronix exercise package.
Exercises, progression and rest periods will be administered and adjusted remotely by the physical therapist using a web-based clinical portal.
|
Participants complete a standard physical therapy evaluation in-person.
They are then provided telerehabilitation equipment for the telerehabilitation intervention.
This intervention utilizes an Xbox Kinect sensor and tablet-based exercise software called Jintronix.
The Jintronix exercise library includes an array of exercise activity options for varying functional levels.
Exercise activities could be completed in sitting or standing postures and includes activities which focused on active range of motion, strength, balance, or calisthenic movements.
Each activity requires the participant to complete a goal-directed game or replicate movements of an on-screen avatar.
The therapist will adjust and progress the home exercise program using information provided by the Jintronix and the participant's verbal reports during clinical video teleconferencing.
At the end of the intervention, the therapist will complete in-person discharge assessments.
Participants complete standard in-person physical therapy evaluation, follow-up, and treatment.
Therapeutic exercise and activities will be prescribed to participants to perform at home between standard follow-up treatment appointments.
At the end of the intervention, the physical therapist will complete in-person discharge assessments.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Multiple Sclerosis Walking Scale-12 (MSWS-12)
Time Frame: Change after 12-week intervention
|
This questionnaire has 12 items and measures self-reported walking ability in MS.
The questions assess the limitations of a patient's walking due to MS during the past 2 weeks.
Each item ranges from 1 to 5 and the higher the sum, the more severe the degree of limitation.
|
Change after 12-week intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Short Physical Performance Battery (SPPB)
Time Frame: Change after 12-week intervention
|
The test involves assessments of clinician rated strength tests of standing balance, timed 3 meter walk, and five chair rise repetitions.
The rating scale starts at "0" indicating no performance or low performance ranging to as score of "4" indicating high performance.
The rating scale ranges from 0 to 12.
|
Change after 12-week intervention
|
25-Foot Walk Test (25FWT)
Time Frame: Change after 12-week intervention
|
The patient is instructed to walk 25 feet as fast as safely possible.
Scoring the 25FW is the average of 2 trials that are performed consecutively.
If necessary, assistive devices are allowed to be used.
|
Change after 12-week intervention
|
Modified Fatigue Impact Scale (MFIS)
Time Frame: Change after 12-week intervention
|
This is a standard measure used to measure fatigue.
The scale consists of 21 items, with 10 items related to mental fatigue, and 11 items relating to physical and social fatigue.
The scoring ranges between 0 and 82, a high score reflecting greater impact.
|
Change after 12-week intervention
|
Veteran Rand 12 Quality of Life Measure (VR-12)
Time Frame: Change after 12-week intervention
|
This 12-item questionnaire has eight principal physical and mental health domains including general health perceptions, physical functioning, role limitations due to physical and emotional problems, bodily pain, energy-fatigue, social functioning, and mental health.
The 12 items is summarized into two sub-scores measuring physical health and mental health.
|
Change after 12-week intervention
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Travel
Time Frame: Start of participation
|
Patient reported estimates of commute to medical facility.
|
Start of participation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Mitchell Wallin, MD, Washington DC VAMC
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 1, 2016
Primary Completion (ACTUAL)
October 1, 2019
Study Completion (ACTUAL)
January 1, 2021
Study Registration Dates
First Submitted
August 28, 2018
First Submitted That Met QC Criteria
August 29, 2018
First Posted (ACTUAL)
August 31, 2018
Study Record Updates
Last Update Posted (ACTUAL)
April 8, 2021
Last Update Submitted That Met QC Criteria
April 5, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1846
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Telerehabilitation
-
Saglik Bilimleri UniversitesiCompletedQuality of Life | Fatigue | Muscle Weakness | Pulmonary Disease | COPD | Respiratory Disease | Dyspnea | Muscle Strength | Functional Capacity | Severe Chronic Obstructive Pulmonary Disease | Motor Imagery | Muscle; AccessoryTurkey
-
Marmara UniversityEnrolling by invitationHemiparetic Cerebral PalsyTurkey
-
Bright Cloud International CorpNational Cancer Institute (NCI); Rutgers, The State University of New JerseyRecruitingCognitive Impairment, MildUnited States
-
University of Eastern FinlandOulu University Hospital; Kuopio University HospitalRecruiting
-
Instituto Mexicano del Seguro SocialRecruitingNeck Pain | Neck SprainMexico
-
University of MinnesotaRecruitingTemporomandibular Disorder | TMJ Disc Displacement With Reduction | TMJ Disc Displacement Without Reduction | Masticatory Myofascial Pain | TMJ Arthralgia | TMD HeadacheUnited States
-
VA Office of Research and DevelopmentNot yet recruiting
-
University Hospital, GrenobleNot yet recruitingChronic Thromboembolic Pulmonary Hypertension
-
Aalborg UniversityViborg Regional Hospital; Aage and Johanne Louis-Hansens Foundation; Laboratory... and other collaboratorsRecruiting
-
University of California, Los AngelesMoss Rehabilitation Research InstituteCompleted